A proposal that would change how food companies introduce new ingredients into the American food supply has cleared White House review, the last procedural step before a rule can be published.
The Office of Information and Regulatory Affairs completed its review of FDA's proposed rule, "Substances Generally Recognized as Safe," according to a notice posted to the OMB website on July 31. The proposal carries the regulatory identifier RIN 0910-AJ02 and had been under OIRA review since FDA submitted it on December 1, 2025.
Clearing OMB is not publication and not adoption. The text has not been released; the public has not seen the specific provisions as cleared, and a proposed rule still faces a comment period, potential revision, and a separate final rule before anything takes effect.
The Pathway Being Rewritten Lets Companies Decide for Themselves
The Generally Recognized as Safe pathway is a decades-old feature of food law that most shoppers have never heard of, and understanding it is the whole story.
Under current practice, a manufacturer that wants to add a substance to food can conclude on its own, usually with a panel of experts it selects, that the substance is generally recognized as safe for its intended use. If it reaches that conclusion, it can market the ingredient without any premarket approval from FDA.
The company may voluntarily submit a GRAS notice to the agency, which then reviews it and may issue what is known as a no-questions letter. That voluntary notification procedure replaced an older affirmation petition process under a 2016 final rule. But submission remains optional. A company can self-affirm and never tell FDA the ingredient exists.
The result is that neither regulators nor the public have a complete inventory of what is in the food supply. This is not a new observation. The Government Accountability Office reported in 2010 that FDA is not required to review GRAS substances and that companies may make such determinations without the agency's approval or knowledge, and it recommended strengthening oversight. Industry has defended the arrangement as a workable system that lets well-characterized ingredients reach market without unnecessary delay.
The Provisions the Agency Has Already Described Publicly
The cleared text is not public, but the government has described its intent in the Unified Agenda, and that is a legitimate basis for reporting so long as the distinction is kept clear.
According to those public descriptions, the proposed rule would make notification mandatory for most substances purported to be GRAS in human and animal food. Exemptions would be allowed for substances already listed by FDA, substances that have received a no-questions letter, or substances covered by an existing regulation.
The proposal would also require FDA to maintain and update a public-facing inventory of GRAS notices and their conditions of intended use, and would clarify the process by which the agency determines that a substance is not GRAS. The action was first listed in the Unified Agenda in September 2025.
What is unknown is how the cleared version differs from those descriptions, how OIRA review may have modified it, what compliance timelines it sets, whether ingredients already on the market under self-affirmed determinations would be grandfathered, and how FDA would resource a mandatory notification system. Those details matter enormously and are not yet public. A projected publication date appears in the Unified Agenda, but such dates are goals rather than commitments.
The Practical Stakes for a Grocery Cart
For households, the honest answer is that nothing changes today, and it may be years before anything does.
No ingredient is being removed from the food supply. No product is being recalled. This is a rulemaking milestone, and rulemaking is slow by design. A published proposal would face a comment period, and a final rule would follow at an unspecified date, with compliance dates after that.
What the proposal would eventually change is transparency. A mandatory notification requirement plus a public inventory would mean regulators and researchers could see the full universe of substances entering food, rather than an incomplete voluntary sample. That is the practical public health benefit being pursued: not that any specific additive is unsafe, but that nobody currently knows the full list.
Readers who want to act on ingredient concerns now have ordinary tools rather than regulatory ones. Ingredient statements on packaged food are required and disclose what is in a product. FDA publishes its existing inventory of voluntarily submitted GRAS notices. People with specific medical reasons to avoid a substance should work with a clinician or registered dietitian rather than relying on general internet claims about additives, which are frequently overstated in both directions.
The Wider Regulatory Moment This Sits In
The GRAS proposal is not moving alone, which is context worth having.
On August 3, HHS and FDA sent a whitepaper titled "Proposed Definition of Ultra-Processed Food" to OIRA, placing a federal definition formally under review. A legal definition would give agencies a category to write rules against, though reporting has indicated the administration may ultimately adopt an existing research definition instead. Because the UPF action is framed as proposed, there may be an opportunity to comment on the whitepaper before any definition is finalized.
Taken together, these are among the most significant proposed changes to federal food ingredient policy in many years. Neither is finished. Proposals clear OMB and then stall, get published and then get substantially rewritten after comment, or get withdrawn by a later administration.
MedicalDaily will report the proposed rule when FDA publishes it in the Federal Register, at which point the actual provisions, the comment deadline and the compliance timeline become knowable rather than inferred.
Frequently Asked Questions
What happened? FDA's proposed rule on substances generally recognized as safe completed White House regulatory review on July 31.
Does that mean the rule is in effect? No. It has not been published, and a proposed rule still requires public comment and a separate final rule before taking effect.
What is GRAS? A pathway that lets manufacturers determine on their own that a food substance is safe for its intended use and market it without FDA premarket approval.
What would change? Public descriptions indicate the rule would make GRAS notification to FDA mandatory for most substances and require a public inventory of those notices.
Do we know the exact text? No. The cleared version has not been released, and its specific provisions and timelines are unknown.
Is any ingredient being pulled from stores? No. This is a rulemaking step, not a safety action against a product.
When could it publish? No date has been announced. The Unified Agenda lists a projected date, but those are goals rather than commitments.
